SCHEMBL3030223

SCHEMBL3030223

C=CCC(=O)O[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27669543 0.82 HTT (0.33)
SCHEMBL18227158 0.78
SCHEMBL3150633 0.78
SCHEMBL11316033 0.75
SCHEMBL252925 0.73 HTT (0.35)
SCHEMBL7559774 0.73 HTT (0.35)
SCHEMBL4715987 0.72
SCHEMBL10720112 0.72 TSHR (0.42)
SCHEMBL11970000 0.70 HTT (0.42)
SCHEMBL21609601 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1700922-B1 3-Substituted 5-Nitroindole derivatives and labeled oligonucleotide probes containing them ROCHE DIAGNOSTICS GMBH (DE) 2016-08-24 EP claimed
EP-2266958-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2010-12-29 EP claimed
US-7695980-B2 Chemiluminescent compounds and their use ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2010-04-13 US claimed
EP-1646609-B1 NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE ROCHE DIAGNOSTICS GMBH (DE) 2009-10-14 EP claimed
US-7563902-B2 Chemiluminescent compounds and their use ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2009-07-21 US claimed
US-20060199833-A1 Novel chemiluminescent compounds and their use ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2006-09-07 US claimed
US-20060199223-A1 storage stability; immunoassays ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2006-09-07 US claimed
US-20060172358-A1 Novel chemiluminescent compounds and their use ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2006-08-03 US claimed
EP-1149069-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP claimed
WO-2000035858-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO claimed
EP-0593452-A1 METHOD FOR PREPARING A METAL-RADIONUCLIDE-LABELLED PROTEIN MALLINCKRODT MEDICAL, INC. (US) 1994-04-27 EP claimed
EP-0593452-A4 METHOD FOR PREPARING A METAL-RADIONUCLIDE-LABELLED PROTEIN. MALLINCKRODT MEDICAL INC (US) 1992-08-31 EP claimed
WO-1991007991-A1 METHOD FOR PREPARING A METAL-RADIONUCLIDE-LABELLED PROTEIN MALLINCKRODT MEDICAL, INC. (US) 1991-06-13 WO claimed
EP-3060545-B1 METHOD FOR SYNTHESISING A MERCAPTAN BY ADDING HYDROGEN SULPHIDE TO AN OLEFIN ARKEMA FRANCE (FR) 2020-09-23 EP disclosed
US-9663461-B2 Method for synthesising a mercaptan by adding hydrogen sulfide to an olefin ARKEMA FRANCE (FR) 2017-05-30 US disclosed
US-20160257646-A1 METHOD FOR SYNTHESISING A MERCAPTAN BY ADDING HYDROGEN SULFIDE TO AN OLEFIN ARKEMA FRANCE (FR) 2016-09-08 US disclosed
WO-2000035858-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO disclosed
EP-0593452-A1 METHOD FOR PREPARING A METAL-RADIONUCLIDE-LABELLED PROTEIN MALLINCKRODT MEDICAL, INC. (US) 1994-04-27 EP disclosed
EP-0593452-A4 METHOD FOR PREPARING A METAL-RADIONUCLIDE-LABELLED PROTEIN. MALLINCKRODT MEDICAL INC (US) 1992-08-31 EP disclosed
WO-1991007991-A1 METHOD FOR PREPARING A METAL-RADIONUCLIDE-LABELLED PROTEIN MALLINCKRODT MEDICAL, INC. (US) 1991-06-13 WO disclosed